David Schultz, MD
Interventional Cardiology · Birmingham, ALNPI 1568436301
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,800 of the $18,641 with a category attached, or 68.7%. Amgen accounts for 73.3% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $14,059 and has fallen 97.8% since, to $314 in 2025.
Across 390 payments — averaging $47.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$14K
- Novartis$2K
- Johnson & Johnson$617
- Pfizer$319
- Merck$261
- AstraZeneca$260
- plus $2K from 26 others
Across 17 payments — averaging $4466.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$76K
What the payments were for
- Speaking & faculty fees$12,80069%
- Food & beverage$5,83631%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 44 | $13,657 |
| Novartis | 165 | $1,967 |
| Johnson & Johnson | 37 | $617 |
| Pfizer | 21 | $319 |
| Merck | 17 | $261 |
| AstraZeneca | 16 | $260 |
| Boehringer Ingelheim | 17 | $256 |
| Sanofi-aventis U.S. LLC | 11 | $180 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $155 |
| E.r. Squibb & Sons, L.L.C. | 10 | $151 |
| Abbott | 4 | $145 |
| Irhythm Technologies, Inc. | 4 | $70 |
| Inari Medical, Inc. | 3 | $57 |
| Kowa Pharmaceuticals America, Inc. | 4 | $53 |
| Amarin Pharma, Inc. | 4 | $53 |
| Impulse Dynamics (USA) Inc. | 3 | $45 |
| Astellas Pharma US Inc | 3 | $43 |
| Boston Scientific | 1 | $36 |
| Medtronic | 1 | $36 |
| Akcea Therapeutics, Inc. | 2 | $34 |
| Vifor Pharma, Inc. | 2 | $29 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Reflow Medical Inc | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Novo Nordisk | 1 | $22 |
| GSK | 1 | $22 |
| Bayer | 1 | $21 |
| Lundbeck LLC | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,641 in reported general payments places this provider in the 75th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 781 | $637,901 |
| XareltoRivaroxaban | 188 | $173,060 |
| EntrestoSacubitril/Valsartan | 122 | $117,039 |
| Repatha SureclickEvolocumab | 90 | $70,174 |
| JardianceEmpagliflozin | 25 | $31,806 |
| MultaqDronedarone Hcl | 19 | $31,740 |
| Repatha SyringeEvolocumab | 26 | $14,182 |
| Voriconazole | 12 | $12,906 |
| Metoprolol Succinate | 460 | $7,526 |
| Atorvastatin Calcium | 454 | $7,307 |
| Bumetanide | 120 | $6,848 |
| Bisoprolol Fumarate | 162 | $6,827 |
| Flecainide Acetate | 68 | $6,556 |
| Ranolazine ErRanolazine | 73 | $6,529 |
| Midodrine Hcl | 55 | $5,383 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $319 | $637,901781 claims |
| Johnson & JohnsonXarelto | $617 | $173,060188 claims |
| NovartisEntresto | $1,967 | $117,039122 claims |
| Boehringer IngelheimJardiance | $256 | $31,80625 claims |
| Sanofi-aventis U.S. LLCMultaq | $180 | $31,74019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Birmingham
- Gary RoubinBirmingham$157K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
- Abdullah MahmoodBirmingham$61K
- Ali EbrahimiBirmingham$55K
- Jacob TownsendBirmingham$52K
- Kamran AliBirmingham$47K
- Mouhamed SabouniBirmingham$44K
- Tushar MishraBirmingham$17K
- Arka ChatterjeeBirmingham$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.